about
Localization of the adhesion receptor glycoprotein Ib-IX-V complex to lipid rafts is required for platelet adhesion and activationPronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trDynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score systemTherapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosisRandomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia.REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia.Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDFirst report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndromeImplications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blastCharacteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndromePrognostic impact of RAS mutations in patients with myelodysplastic syndrome.Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromesBiological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience
P50
Q28629042-6895C9CC-2FF5-40C4-8002-F36ECE58AD43Q28741513-F390D9A2-DFA9-46D0-B061-CD3303BBDE69Q30277009-CD7BC7B6-B329-4884-8447-DF2EA8DD457AQ31033077-02139002-8552-4E66-B105-F54C545B1EFDQ33384955-6CF30503-28D6-4BB0-BAA9-E226EF8562D3Q33387517-AED6592C-BD5A-41B3-A28E-A4EE3F5A2758Q33387519-81F49D49-5D72-47DD-A3ED-CC4F255489ADQ33390293-73D8E09C-8B27-4770-BB87-E0D9E9E00889Q33391401-E9CA4285-97DB-4816-9A0A-6B268F95F1F0Q33399233-0B618283-8D86-4E90-851D-89063495727AQ33400570-F7181D5C-F75B-45D2-92A0-71AB7925DDBEQ33408184-EDED4B54-884E-4816-B018-74EDE9E6DD0AQ33416642-AC005666-5DA9-4ACE-861B-33E39D7C6DEFQ33418735-36875B54-1241-46C4-9202-D2773AAEA878Q33420436-25EC8D94-8A82-4B0B-820B-0C9DAAA33E1CQ33428940-55EC7BD4-9B21-461B-878A-E37630E394F1Q33435191-48871704-41E2-4C4F-BDA9-57D97078CD6BQ33702412-579692F9-2435-4425-8F32-0D47FC64D015Q33730841-7E53FACF-5F0D-43E2-8629-2518890242B4Q33764269-69BA62AF-91D9-499E-8BF7-556A27242D6FQ33798909-8CC8D52D-14AB-49FF-A3E7-06BE323D581CQ33843477-C057A329-95A9-44E3-9C3E-4FF171D9F3CBQ33843731-C689DD16-15C9-4616-851F-71DB6A58F995Q33843955-36B76063-EBAE-415D-AB53-38555325C5A1Q33843996-428E60CC-009B-4419-A88D-D9EA57DBD5F1Q33844007-14529742-14DB-4167-9CE7-F25551051B52Q33844041-D6B33BCD-2C58-49F9-BA1E-42DBC7E8422CQ33856597-77FA15E6-3C58-4187-B43E-EE8AA192F659Q33871210-BF060BA0-25D1-4E13-8FAA-3C6A75317FDBQ33876297-6EEB9FA6-9BF2-4B65-AAEE-A545C4B868AAQ33914289-85D17C87-181D-43F8-B9E0-2156F1A43EDDQ33919884-A3A17A0F-04AE-45DC-A43C-7C5C61A52B96Q33949752-FEE4FA0A-A35C-44E8-8E68-BCCC02EE1184Q33968321-5F0BEDED-E1C1-41B7-99DD-10FCDCE1D9E6Q33968372-7026CF3D-9409-455C-8EA1-9FB47A8240B6Q33995610-DC6003ED-E25B-4DF9-8D79-B00399E9F83EQ34011740-B8B3E5A0-1538-478C-8EEB-840E29896E14Q34018544-9D0C344F-0877-4FA0-9190-2E5FA4EA1EDEQ34018590-90FAD6B4-B5FF-4EEB-88C6-13246D881EA2Q34022125-93C2FC2F-F7D9-4DD8-A3E6-02CEF7426842
P50
name
Gautam Borthakur
@ast
Gautam Borthakur
@en
Gautam Borthakur
@nl
type
label
Gautam Borthakur
@ast
Gautam Borthakur
@en
Gautam Borthakur
@nl
prefLabel
Gautam Borthakur
@ast
Gautam Borthakur
@en
Gautam Borthakur
@nl